Clinical Trials Search
A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia
Primary Objective: 1) To estimate the complete response rate following treatment with CPX-351. Important Secondary Objectives: 1) To evaluate the safety and tolerability of CPX-351. 2) To estimate minimal residual disease burden following treatment with CPX-351. 3) To estimate the progression free survival (PFS) following treatment CPX-351. 4) To estimate the overall survival (OS) following treatment with CPX-351.